Coromandel International (COROMANDEL) investor relations material

Executive summary

• Q3 FY26 revenue from operations rose 27% year-over-year to ₹8,779 crore, with EBITDA up 12% to ₹805 crore and PAT down 4% to ₹488 crore; India’s GDP growth was 7.4% and government policies remained supportive for agriculture.

• For YTD Dec'25, revenue increased 33% to ₹25,476 crore, EBITDA grew 24% to ₹2,738 crore, and PAT rose 21% to ₹1,784 crore.

• Board approved unaudited financial results for the quarter and nine months ended December 31, 2025, and declared an interim dividend of ₹9 per equity share.

• Extended monsoon and crop damage in South India impacted agri input consumption, but Rabi sowings and reservoir levels improved year-over-year.

• Government subsidy allocations for fertilizers remain robust, with INR 186,000 crore for FY25-26 and INR 171,000 crore for FY26-27.

Financial highlights

• Consolidated revenue from operations for the quarter was ₹8,779.45 crore, up from ₹6,935.19 crore year-over-year; nine-month consolidated revenue was ₹25,475.88 crore.

• Consolidated EBITDA for Q3 was ₹805 crore (vs. ₹722 crore YoY); nine-month EBITDA was ₹2,738 crore (vs. ₹2,202 crore YoY).

• Net profit after tax for Q3 was ₹488 crore (vs. ₹508 crore YoY); nine-month net profit was ₹1,784 crore (vs. ₹1,476 crore YoY).

• Basic EPS for the quarter was ₹17.14; for nine months: ₹62.85.

• Interim dividend of ₹9 per equity share declared, with record date set for February 4, 2026.

Outlook and guidance

• Annualized EBITDA guidance for fertilizer business remains at INR 5,000–5,500 per ton, with potential to reach INR 6,500 post-commissioning of new phosphoric acid plant.

• Expectation of sulfur price moderation in coming quarters; backward integration projects to sustain targeted EBITDA benefits.

• Crop protection business targets 20–25% annual growth in domestic B2C and continued export-led growth, especially in mancozeb.

• Forward-looking statements indicate expectations of continued growth, but actual results may vary due to market, regulatory, and operational factors.

• Management notes that consolidated figures for the current period may not be comparable to previous periods due to the acquisition of NACL.